Inhibiting Apolipoprotein CIII-Induced Beta Cell Death
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Voltage-gated calcium channels in pancreatic β cells are hyperactivated by apolipoprotein CIII, leading to β cell apoptosis and contributing to the development of diabetes, with existing methods failing to effectively inhibit this hyperactivation.
Innovation Solution
Identifying candidate compounds that inhibit the apolipoprotein CIII-induced increase in density and conductivity of Ca v 1 channels in pancreatic β cells by contacting insulin-secreting cells with apolipoprotein CIII and test compounds, while also using inhibitors of scavenger receptor class B type I (SRBI) expression or activity, Ca v 2 and/or Ca V 3 channel blockers, Src kinase, protein kinase A (PKA), and β1 integrin to selectively down-regulate channel activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If apolipoprotein CIII is present to increase density and conductivity of Ca v 1 channels, then channel activity is enhanced, but this leads to beta cell apoptosis and diabetes development
Solution Approach 1:
The patent identifies that while ApoCIII-induced CaV1 channel hyperactivation is harmful and leads to beta cell death, this same pathway can be targeted to identify protective compounds. By screening compounds that specifically inhibit ApoCIII-induced channel hyperactivation (rather than blocking all CaV1 channels), the harmful effect is converted into a therapeutic opportunity where selective inhibition protects beta cells while preserving normal physiological function.
Solution Approach 2:
The patent applies local quality by developing compounds with selective inhibition capability - they specifically target ApoCIII-induced channel hyperactivation in diabetic conditions while leaving normal physiological CaV1 channel function intact. This is achieved through screening assays that distinguish between pathological and physiological channel activation, allowing compounds to exhibit different inhibitory effects in different contexts.
2Reliability
If existing methods are used to inhibit Ca v 1 channels, then channel activity is reduced, but they fail to effectively inhibit ApoCIII-induced hyperactivation
Solution Approach 1:
The patent employs dynamic screening assays that measure channel activity under different conditions - specifically comparing baseline activity, ApoCIII-induced hyperactivation, and compound inhibition effects. This dynamic approach allows identification of compounds that exhibit conditional inhibition - blocking pathological hyperactivation while preserving physiological function - rather than static inhibition of all channel activity.
Solution Approach 2:
The patent changes the parameter being measured from simple channel blockage to selective inhibition of ApoCIII-induced hyperactivation. By using assays that specifically measure the ability to inhibit ApoCIII-induced increases in channel density and conductivity, the patent identifies compounds with precise inhibitory profiles that target pathological rather than physiological channel activity.
3Ease of operation
If compounds are screened without considering SRBI inhibition, then screening is simpler, but compounds cannot selectively target ApoCIII-induced hyperactivation
Solution Approach 1:
The patent segments the screening process into multiple distinct assays: (1) baseline CaV1 channel function assessment, (2) ApoCIII-induced hyperactivation measurement, (3) compound inhibition testing, and (4) SRBI inhibition assessment. This segmentation allows each aspect to be measured independently and combined to identify compounds with the desired selective inhibition profile, achieving both precision and operational feasibility.
Solution Approach 2:
The patent uses SRBI status as an intermediary marker to identify compounds that specifically target the ApoCIII-SRBI-CaV1 channel pathway. By measuring SRBI inhibition alongside channel activity, the patent can distinguish compounds that act through this specific pathway from those with non-specific effects, enabling selective identification of therapeutic candidates.
Data Source
Figure 1a~1d
Figure 2a~2d
Figure 3a~3f
AI summary
The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.